In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Sempra’s current price exceeds the PERT-weighted fair value by 32.4%, indicating overvaluation based on dominant high-confidence DCF and analyst target methods. Financial health scores, notably low efficiency and growth, signal operational and expansion challenges. Monte Carlo analysis presents negligible downside risk below current price, suggesting price stability despite valuation concerns.